Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a pioneering specialty pharmaceutical company dedicated to developing and commercializing next-generation, abuse-deterrent products aimed at treating chronic pain and other serious medical conditions. Leveraging its proprietary DETERx® technology platform, Collegium creates formulations designed to mitigate the risks associated with the misuse and abuse of prescription medications. The DETERx technology maintains the extended-release and safety profiles of commonly abused drugs, such as opioids and amphetamines, even when subjected to tampering methods like crushing, chewing, or dissolving.
Collegium's lead product, Xtampza ER™, is an extended-release, oral formulation of oxycodone that incorporates abuse-deterrent properties. The company's product portfolio also includes the Nucynta® Products (extended-release and immediate-release formulations of tapentadol), Belbuca® (buccal film for severe chronic pain), and Symproic® (for opioid-induced constipation).
In recent news, Collegium announced its financial results for the quarter ended September 30, 2023, reporting a solid financial performance and an optimistic outlook for 2025 and 2026. The company achieved record quarterly revenue for Belbuca and has initiated an Accelerated Share Repurchase (ASR) program, further demonstrating its commitment to returning value to shareholders. The extension of Nucynta's regulatory exclusivity through July 2026 has also strengthened the company's future market positioning.
Headquartered in Stoughton, Massachusetts, Collegium continues to focus on operational excellence and disciplined capital deployment to enhance shareholder value. The company remains committed to improving patient outcomes while addressing the growing challenges of prescription drug abuse.
For more details and the latest updates, visit Collegium Pharmaceutical's website.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the Jefferies Global Healthcare Conference in New York, NY, on June 5-6, 2024. The company's management will engage in a fireside chat on June 5, 2024, at 9:30 a.m. ET. The event will be webcast live and available on Collegium's Investors section. Additionally, a replay of the webcast will be accessible for 90 days post-event.
Collegium Pharmaceutical, Inc. announced a $35 million Accelerated Share Repurchase (ASR) program with Jefferies to buy back common stock as part of a $150 million repurchase program. The company aims to enhance shareholder value by leveraging its capital deployment strategy. The ASR agreement will result in Collegium receiving 888,889 shares initially, with the final number based on stock prices during the term.
Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.
Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What is Collegium Pharmaceutical, Inc.?
What is DETERx® technology?
What are the main products offered by Collegium?
What recent financial achievements has Collegium reported?
Where is Collegium Pharmaceutical headquartered?
How does Collegium's DETERx® technology help in preventing drug abuse?
What is Xtampza ER™?
How does Collegium Pharmaceutical return value to its shareholders?
What is the significance of Nucynta's regulatory exclusivity extension?
How can I stay updated on Collegium Pharmaceutical's latest news?
